The serotonin type 3 receptor (5-HT 3 R) is a member of the cys-loop ligand-gated ion channel (LGIC) superfamily. Like almost all membrane proteins, high-resolution structural data are unavailable for this class of receptors. We have taken advantage of the high degree of homology between LGICs and the acetylcholine binding protein (AChBP) from the freshwater snail Lymnea stagnalis, for which high-resolution structural data are available, to create a structural model for the extracellular (i.e., ligand-binding) domain of the 5-HT 3 R and to perform a series of ligand docking experiments to delineate the architecture of the ligand-binding site. Structural models were created using homology modeling with the AChBP as a template. Docking of the antagonist granisetron was carried out using a Lamarckian genetic algorithm to produce models of ligand-receptor complexes. Two energetically similar conformations of granisetron in the binding site were obtained from the docking simulations. In one model, the indazole ring of granisetron is near Trp90 and the tropane ring is near Arg92; in the other, the orientation is reversed. We used double-mutant cycle analysis to determine which of the two orientations is consistent with experimental data and found that the data are consistent with the model in which the indazole ring of granisetron interacts with Arg92 and the tropane ring interacts with Trp90. The combination of molecular modeling with double-mutant cycle analysis offers a powerful approach for the delineation of the architecture of the ligand-binding site.
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The serotonin type 3 receptor (5-HT 3 R) is a member of the cys-loop ligand-gated ion channel gene family, which includes the muscle and neuronal nicotinic acetylcholine receptors, the glycine receptor, and the GABA A receptor (Connolly and Wafford, 2004; Lester et al., 2004) . Two different subunits, termed 5-HT 3A and 5-HT 3B , have been described previously (Reeves and Lummis, 2002) . The 5-HT 3A subunit forms functional receptors with the appropriate pharmacological properties when expressed in Xenopus laevis oocytes or mammalian cells. However, there are some differences between the properties of the expressed homomeric receptors and 5-HT 3 Rs in some, but not all, neurons. Perhaps the most significant difference is that the single-channel conductance of the expressed receptors is in the subpicosiemen range, whereas that of the receptors in many (but not all) neurons is in the range of 10 to 20 pS (Yang et al., 1992; Hussy et al., 1994) . This difference, along with the fact that other members of the cys-loop LGIC family are composed of several different subunits, led to the search and subsequent discovery of an additional 5-HT 3 R subunit, now termed the 5-HT 3B subunit (Davies et al., 1999; Dubin et al., 1999) .
When expressed by itself, the 5-HT 3B subunit does not form functional receptors. When the 5-HT 3B subunit is coexpressed with the 5-HT 3A subunit, the ligand-binding properties of the expressed receptors are identical to those resulting from expression of the 5-HT 3A subunit alone (Brady et al., 2001 ) and of native 5-HT 3 Rs. However, whereas homomeric 5-HT 3A Rs have single-channel conductances in the subpicosiemen range, the heteromeric receptors (i.e., 5-HT 3A ϩ 5-HT 3B subunits) exhibit single channels with conductances of approximately 15 pS, as seen in many neuronal 5-HT 3 Rs (Davies et al., 1999; Dubin et al., 1999) . Initial examination of the pattern of expression of the 5-HT 3B subunit showed that it was expressed in the same tissues and brain regions as the 5-HT 3A subunit, suggesting that all 5-HT 3 Rs are heteromeric. However, subsequent expression profiling studies with better spatial resolution (for review, see van Hooft and Yakel, 2003) have cast doubt on the notion that 5-HT 3 Rs in the central nervous system are always heteromeric, so the question of subunit composition of "bona fide" 5-HT 3 Rs is by no means settled. However, because the ligand-binding profiles of native, homomeric and heteromeric receptors are identical, the structure of the ligand-binding domain of the two types of expressed 5-HT 3 Rs and those of native receptors are highly similar. Thus, homomeric 5-HT 3A Rs should be an appropriate model for the structure of the ligand-binding domain of native 5-HT 3 Rs.
Over the years, structural models for the 5-HT 3A R and other members of the ligand-gated ion channel family have been developed, mostly based on the extensive amount of data obtained from studies on the acetylcholine receptor [for review, see Karlin (2002) ], and then refined using mutagenesis data from the particular receptor under consideration. At first, these models were not of sufficient resolution to produce detailed models of the architecture of the ligandbinding domains, but the isolation and subsequent determination of the structure at atomic resolution of a homologous acetylcholine-binding protein (AChBP) from the freshwater snail Lymnea stagnalis (Brejc et al., 2001; Smit et al., 2001) has provided a true structure to use as a framework for constructing more realistic models of the extracellular domain of LGICs (Cromer et al., 2002; Le Novere et al., 2002; Maksay et al., 2003; Reeves et al., 2003) .
In the case of AChBP-based models of the 5-HT 3A R (Maksay et al., 2003; Reeves et al., 2003) , ligand-docking simulations produced several orientations of agonists (Reeves et al., 2003) or antagonists (Maksay et al., 2003) in the binding site, and the authors used data obtained from previous mutagenesis studies to evaluate models for consistency with experimental data to select feasible models for receptor-ligand interactions. In this report, rather than using previously obtained data as the determinant of ligand-receptor model feasibility, we use the model itself to guide the design of experiments to test the model employing a variant of doublemutant cycle analysis (Hildago and MacKinnon, 1995) . The results of these experiments can then be used to select the ligand-receptor model that is consistent with experimental data, and thus is most likely to be correct.
Materials and Methods
Molecular Biology and Transfection. A full-length cDNA clone corresponding to the 5-HT 3A(b) form (Hope et al., 1993) of the receptor was isolated from a neuroblastoma N1E-115 cell line cDNA library as described previously (Yan et al., 1999) and subcloned into vector pCI (Promega, Madison, WI). Site-directed mutagenesis was carried out using the QuickChange system (Stratagene, La Jolla, CA) as described previously (Yan et al., 1999) . The nomenclature used to describe mutants is amino acid in wild-type/position/substitution (e.g., W90F). Because the amino terminus of the mature 5-HT 3A subunit is unknown, the amino acid numbering system here includes the signal sequence and has the initial methionine as position 1. Please note that the numbering system for the 5-HT 3A receptor used in a previous study from this laboratory has changed somewhat so that the W90F and R92A mutations in this study correspond to the W89F and R91A mutations, respectively, in the original study (Yan et al., 1999) . Cultures of tsA201 cells, a derivative of the widely-used human embryonic kidney 293 cell line, were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin. Cultures at 30 to 40% confluence were transfected with 20 g of receptor cDNA per 100-mm dish using the calcium phosphate technique (Wigler et al., 1979) . After 12-h exposure to the DNA/calcium phosphate solution, the medium was replaced with fresh medium, and the cells were allowed to grow for another 24 to 36 h before use. Maximal expression was obtained 36 to 72 h after transfection.
Ligand Binding Assays. Transfected cells were scraped from dishes, washed three times with phosphate-buffered saline, and resuspended and homogenized in 2.5 ml of buffer A (154 mM NaCl and 50 mM Tris-HCl, pH 7.4) per 100-mm dish. The homogenate was then used in binding assays or frozen until needed. We observed no change in either ligand affinity or B max values after freezing.
Membranes were incubated for 2 h at 37 o in a total volume of 0.5 ml of buffer A containing the appropriate concentrations of antagonist and radioligand ([ 3 H] granisetron; 85 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA). Binding was terminated by rapid vacuum filtration onto GF/B filters that had been pretreated with 50 mM Tris-HCl, pH 7.4, and 0.2% polyethylenimine, and the filters were washed with 10 ml of ice-cold 50 mM Tris-HCl, pH 7. (Cheng and Prusoff, 1973) : Ligands. The structures of the ligands used in this study are shown in Fig. 3. [ 3 H]Granisetron was obtained from PerkinElmer Life and Analytical Sciences, MDL 72222 from Sigma (St. Louis), and ondansetron from GlaxoSmithKline (Uxbridge, Middlesex, UK).
Molecular Modeling. A structural model of the extracellular domain of the mouse 5HT 3A R was generated using MODELLER ver. 7.7 (Sali and Blundell, 1993) , using the X-ray structure of AChBP as a template [Protein Data Bank code 1I9B (Brejc et al., 2001) ]. The sequence alignment between AChBP and 5HT 3A R monomers was performed with Align2D from the MODELLER suite, which uses a variable gap opening penalty that depends on the three-dimensional structure of the template. All five subunits were modeled simultaneously to ensure structural integrity between subunits at their interfaces. All polar hydrogens, but not nonpolar hydrogens, were included to allow for main-chain hydrogen bonding. The programs PROCHECK and ProSa2003 were used to evaluate the generated models (Laskowski et al., 1993; Sippl, 1993) , and the model that ranked highest by PROCHECK and ProSa2003 was chosen for ligand docking.
Ligand Docking Simulations. 5HT 3 R ligands were docked to each binding site in the chosen model using Autodock 3.0 (Morris et al., 1998) . Solvation parameters were added to the protein coordinate file, and the ligand torsions were defined using the 'Addsol' and 'Autotors' utilities, respectively, in Autodock 3.0. Gasteiger-Marsili charges (Gasteiger and Marsili, 1980) , which uses the united atom representation for nonpolar hydrogens, were applied to ligands before docking. The docking was performed with the initial population size set to 100 with 100 independent runs using otherwise default parameters in the standard protocol on a 30 ϫ 30 ϫ 40-Å grid with spacing of 0.375 Å. The size of the grid gives sufficient freedom for the ligands to be docked in all possible orientations but does not permit them move outside of the binding site. In addition to returning the docked structure, AutoDock also calculates an affinity constant for each ligand-receptor configuration. Images of the receptor with and without docked ligands were produced using the UCSF Chimera package (Pettersen et al., 2004 ) from the Computer Graphics Laboratory, University of California, San Francisco (supported by National Institutes of Health grant P41-RR01081).
Results
The extracellular domain of the 5-HT 3A R was modeled using the known three-dimensional structure of the AChBP from L. stagnalis (Brejc et al., 2001 ) as a template for homology modeling using MODELLER ( Fig. 1) (Sali and Blundell, 1993) . As with models for the 5-HT 3A R reported previously (Maksay et al., 2003; Reeves et al., 2003) , each subunit assumes an immunoglobulin-like fold structure (Fig. 1) . In the AChBP and, by inference, the other members of the cys-loop ligand-gated ion channel family, the ligand-binding domain is at the interface between subunits and is made up of a series of six domains (A-F), three from one subunit (A-C), and three from the adjacent subunit (D-F) (Brejc et al., 2001; Celie et al., 2004) . Consistent with this notion, studies from several laboratories have identified a number of residues at or near the 5-HT 3 R ligand-binding site (Boess et al., 1997; Hope et al., 1999; Yan et al., 1999; Spier and Lummis, 2000; Venkataraman et al., 2002; Yan and White, 2002; Schreiter et al., 2003; Price and Lummis, 2004) that are located in the various binding-site domains in the model.
We used a Lamarckian genetic algorithm (AutoDock; Morris et al., 1998) to create models of antagonist-receptor interactions within the ligand-binding domain using granisetron as the ligand. The models of the 5-HT 3A R/granisetron complex produced by this procedure fall into two broad classes (Fig. 2 and Table 1 ): those with the indazole ring of granisetron near Trp90, and those with the indazole ring near Arg92. Given the various assumptions that underlie the calculations involved in the docking process, using the calculated K i values to discriminate between models is not appropriate, especially when the K i values are very close together.
Double-mutant cycle analysis (Carter et al., 1984) can be used to determine whether a particular residue interacts with a particular portion of a ligand. The underlying logic of this approach is that if residue x in the binding site interacts with residue y on the ligand, then the effect of mutating x should depend upon whether residue y in the ligand is changed. An interaction parameter, ⍀, is calculated from the
, where W indicate wild-type receptor, m indicates mutant receptor, and L1 and L2 indicate the two ligands being compared. An ⍀ value significantly different from 1 indicates an interaction between the functional group on the ligand and the amino acid on the receptor. Although initially used for analysis of the interaction of peptide toxins with K ϩ channels (Hildago and MacKinnon, 1995) , this approach has also been applied to identify points of contact between acetylcholine receptors and peptide toxins (Malany et al., 2000) or d-tubocurarine analogs (Willcockson et al., 2002) .
We have used the interaction of three different ligands (granisetron, MDL 72222, and ondansetron; Fig. 3 ) with wild-type, W90F, and R92A receptors to evaluate the models produced in the docking simulations. These two residues (Trp90 and Arg92) are in loop D of the binding site, and we have shown previously that they play a role in ligand-receptor interactions (Yan et al., 1999) . To a crude approximation, MDL 72222 and ondansetron can be thought of as being structural variants of granisetron. In the case of MDL 72222, the indazole ring of granisetron is "mutated" to a chlorobenzoyl ring, whereas in the case of ondansetron, the tropane ring of granisetron is "mutated" to an imidazole ring. Figure  4 shows the inhibition of [ 3 H]granisetron binding to wildtype, W90F, and R92A receptors by MDL 72222. The W90F mutation markedly reduces the affinity for MDL 72222, whereas the R92A mutation slightly increases affinity for the receptor. Table 2 shows the results of the analysis of the interaction of all three ligands with all three receptors. The W90F mutation reduces the affinity for each ligand, whereas the R92A mutation reduces the affinity of granisetron and ondansetron but increases the affinity for MDL 72222.
The combination of three receptors (wild-type, W90F, and R92A) and three ligands (granisetron, MDL 72222, and ondansetron) gives rise to four double-mutant cycles: a) WT/ W90F/granisetron/MDL 72222, b) WT/W90F/granisetron/ ondansetron, c) WT/R92A/granisetron/MDL 72222, and d) WT/R92A/granisetron/ondansetron. For each cycle, an interaction parameter, ⍀, can be calculated from estimates of the K d (granisetron) and K i (MDL 72222 and ondansetron) values of the relevant receptors. Figure 5 shows the four doublemutant cycles that can be constructed, along with the corresponding ⍀ values. Only two of the cycles have ⍀ values different from 1.0. The WT/R92A/granisetron/MDL 72222 cycle has an ⍀ value of 10.8, and the WT/W90F/granisetron/ ondansetron cycle has an ⍀ value of 2.2. When the structures of the three ligands are examined, these data suggest that the indazole ring of granisetron interacts with Arg92 and the tropane ring of granisetron interacts with Trp90. These data can be used to evaluate the ligand-receptor models obtained from the modeling studies, as will be described below.
Discussion
The ultimate goal of molecular modeling is to produce a model that accurately represents the three-dimensional structure of the protein under study. In cases in which actual structural data are missing, homology-based models using molpharm.aspetjournals.org the structures of related proteins have proven to be a useful approach. In the case of cys-loop LGICs, workers have used the structure of the L. stagnalis AChBP as a template upon which to build structural models of the extracellular (i.e., ligand-binding) domain of the receptors and have then evaluated the models in light of previously obtained mutagenesis data. Using this approach, two groups have produced models of the 5-HT 3A R binding site (Maksay et al., 2003; Reeves et al., 2003) . The lack of publicly available Protein Data Bank coordinate files of these other two models precludes a detailed comparison of our model with the other two. The backbone structures of these models are similar to ours, but there are undoubtedly differences in the orientation of side chains within the structures.
The ligand-docking simulations with the antagonist granisetron produced four clusters of docked structures with calculated K i values in the 2 to 6 nM range, similar to the experimentally obtained K i value for wild-type receptors. Three of the models (clusters 1-3; Table 1 , Fig. 2A ) have granisetron oriented in the binding site such that the indazole ring of granisetron is near Trp90 and the tropane ring is near Arg92, whereas the fourth (cluster 4; Fig. 2B ) has the opposite orientation. Maksay et al. (2003) carried out docking simulations with granisetron with the human, mouse, and guinea pig 5-HT 3A R. They produced several models of the granisetron-receptor complex, and the lowest energy model was one in which the tropane ring of granisetron was near Trp90 and the indazole ring was closer to Arg92, similar to our cluster 4; other, higher-energy models had the opposite orientation, similar to our clusters 1 to 3. However, the authors did not provide information on the either the values of the energies or calculated K i values, so it is not possible to determine the energy relationships of the different reported conformations.
Given that the calculated K i values of the four clusters of structures that were produced in this study are very close to each other, choosing one granisetron orientation over the others based solely on calculated K i values is inappropriate. We chose to test the models using double-mutant cycle analysis. This type of analysis can be used to determine whether or not a particular residue interacts with a particular portion of a ligand (i.e., which parts of a ligand are in close physical proximity to a particular residue). By using three different ligands (granisetron, MDL 72222, and ondansetron), we were able to examine both "halves" of the ligand. The ⍀ value for the WT/R92A/granisetron/MDL 72222 cycle suggests that the indazole ring of granisetron, but not the tropane ring, interacts with Arg92, whereas the ⍀ value for the WT/Trp90/ granisetron/ondansetron cycle suggests that the tropane ring, but not the indazole ring, interacts with Trp90. Note that the use of the three different ligands provides an internal check for the consistency of the results; i.e., two independent cycles with ⍀ values Ͼ1 lead to the same conclusion regarding the orientation of granisetron in the binding site. (Ku, 1966) . The ⍀ value of 10.8 for the WT/R92A and granisetron/MDL 72222 cycle indicates that R92 interacts with the indazole ring of granisetron, whereas the ⍀ value of 2.2 for the WT/ W90F and granisetron/ondansetron indicates that W90F interacts with the tropane ring of granisetron. 15.6 Ϯ 2.5* Thus, although the orientation of granisetron in cluster 4 is not as energetically favorable as the others (at least based on calculations), it is the only orientation that is consistent with the double-mutant cycle data, strongly suggesting that this is the actual orientation of granisetron in the ligand-binding site.
The values of ⍀ from the double-mutant cycle analysis are associated with rather low ⌬⌬G values (approximately Ϫ1.4 kcal/mol for the WT/R92A/granisetron/MDL 72222 cycle, and approximately Ϫ0.5 kcal/mol for the WT/Trp90/granisetron/ ondansetron cycle), indicating that the interactions are quite weak, because of the type interaction (such as van der Waal's or hydrogen bonds) and/or the distance over which the interaction occurs. Similarly weak interactions were observed in a double-mutant cycle analysis of the interaction of d-tubocurarine with the nicotinic acetylcholine receptor (Willcockson et al., 2002) . Reeves et al. (2003) developed a homology-based model of the 5-HT 3 R and carried out docking simulations using serotonin as the ligand. Seven different orientations of 5-HT in the binding site were obtained. In the two orientations that they chose as being most likely, the amino group of the indole ring of 5-HT was close to Trp90, but no part of the agonist was near enough to Arg92 to suggest that an interaction formed between Arg92 and the agonist. In other, less-favored orientations, the hydroxyl group of 5-HT was in a pocket containing Arg92, and the side-chain amine was near Trp90. However, none of the models put the indole ring near Arg92. If the indazole ring of granisetron makes interactions similar to those made by the indole ring of 5-HT, then based upon our model, we would expect that the indole of 5-HT would be near Arg92, which none of the agonist-receptor models shows. One possible nontrivial explanation for this is that because of the allosteric nature of ligand-induced channel gating, agonists and antagonists interact with different conformations of the binding site. Thus, one may not expect identical interactions to be observed for agonists and antagonists.
In the present study, we used double-mutant cycle analysis to evaluate various docked orientations of antagonists. Unfortunately, the fact that agonists induce conformational changes in the receptor makes it impossible to obtain accurate estimates of agonist affinity of wild-type and mutant receptors using ligand-binding assays (Colquhoun, 1998) . As a result, one cannot evaluate models of agonist-receptor interaction using the experimental approach done here. In the absence of a rigorous method of testing proposed structures of agonist-receptor complexes, extension of our model to agonist-receptor interactions is premature at present.
This study shows the power of double-mutant cycle analysis with small molecule ligands of differing structure to probe ligand-receptor interactions in a way that can map differing portions of the ligand onto specific regions of the receptor. In conjunction with molecular modeling studies, an iterative loop of modeling and experimental testing of models can be created that can accelerate the process of elucidating the three-dimensional architecture of a ligand-binding domain. Inclusion of a wide variety of ligands and mutant receptors should allow the examination of the architecture of the entire ligand-binding domain and thus provide useful information for the design of novel pharmacological agents with both high affinity and high specificity for use as therapeutic agents.
